Parecoxib, A Selective Cyclooxygenase Inhibitor, Attenuates C-Jun N-Terminal Kinase Activation in Experimental Subarachnoid Hemorrhage Induced Early Brain Injury

Chih-Zen Chang1,2, Shu-Chuan Wu2, Chih-Lung Lin1,2 and Aij-Lie Kwan1,2

1Department of Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan
2Division of Neurosurgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Corresponding author: Chih-Zen Chang, Department of Neurosurgery, Kaohsiung Medical University Hospital, No.100, Tzyou 1st Road, Kaohsiung, Taiwan, Republic of China, Tel: 886-7-3215049; Fax: 886-7-3215039; E-mail: changchihzen2002@yahoo.com.tw

Received date: May 06, 2015; Accepted date: June 09, 2015; Published date: June 15, 2015
Copyright: ©2015 Chang CZ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Increased evidence has disclosed early brain injury (EBI) might determine the outcome of patients suffering from aneurismal subarachnoid hemorrhage (SAH). This study is of interest to examine the efficacy of parecoxib, a cyclooxygenase-2 (COX-2) inhibitor, on SAH-induced EBI.

Methods: The rodent SAH model was employed. 500/1000/2000ug/kg/day parecoxib was administered via osmotic mini-pump. CSF samples were collected to examine IL-1β, IL-6, IL-8 and TNF-α. Cerebral cortex was harvested for C-Jun N-terminal kinase (cJNK), NMDARs (western blot), B-cell lymphoma 2 (Bcl-2), caspases (rt-PCR) measurement.

Results: Parecoxib dose-dependently reduced the bio-expression of cJNK when compared with the SAH groups. No significant differences were found in the levels of IL-8 among the experimental groups. The levels of IL-1β, IL-6 and TNF-α were increased in animals subjected to SAH, compared with healthy controls, but not in the medium- and high-dose parecoxib treatment group. Moreover, the levels of TNF-α in the SAH-only and SAH-plus vehicle groups were significantly elevated, and treatment with parecoxib (1000ug/kg) reduced the level of healthy controls. Cleaved caspase-3 and -9a were both significantly reduced in 2000ug/kg parecoxib treatment groups. Likewise, NMDAR-2a was significantly suppressed in parecoxib treatment SAH groups (p <0.01).

Conclusion: Treatment with parecoxib exerts its neuroprotective effect through the dual effect of inhibiting cJNK-activated neuro-inflammation and reduced mitochondrion-related caspase-9a expression. Besides, parecoxib decreased CSF levels of TNF-α and IL-1β, which contributes to the anti-delayed vasoconstriction effect. This study lends credence to support the COX-2 inhibitor could attenuate SAH-induced EBI.

Keywords: Early brain injury; Parecoxib; C-Jun N-terminal kinase; Cyclooxygenase 2; N-methyl-D-aspartate receptor; Subarachnoid hemorrhage

Abbreviations

BA: Basilar Artery; BAX: BCL2-Associated X Protein; Bcl-2: B-Cell Lymphoma 2; Caspases: Cysteine Requiring Aspartate Proteases; cJNK: C-Jun N-Terminal Kinase; COX: Cyclooxygenase; CSF: Cerebrospinal Fluid; EBI: Early Brain Injury; ET: Endothelin; GFAP: Glial Fibrillary Acidic Protein; HRP: Horseradish Peroxidase; IEL: Internal Elastic Lamina; IL-1& -6: Interleukin 1 and 6; MAPK: Mitogen-Activated Protein Kinase; MCP-1: Monocyte Chemoattractant Protein-1; NMDA: N-Methyl-d-Aspartate; Nrf2: Nuclear Factor-Erythroid Related Factor 2; PBS: Phosphate-Buffered Saline; PGs: Prostaglandins; RANTES: Regulated-upon-Activation Normal T Cell Expression and Presumably Secreted; ROS: Reactive Oxygen Species; SAH: Subarachnoid Hemorrhage; TNF-α: Tumor Necrotic Factor-α.

Introduction

Delayed ischemic neurological deficit, and acute cerebral ischemia subordinate to subarachnoid hemorrhage (SAH) has become a major disability in patients following a ruptured aneurysm [1-5]. Despite more than fifty years of studies focusing on the correction and prevention of delayed vasospasm, the efforts, in a multifaceted way, trying to reverse this condition, have proven to illustrate poor outcome. Increased evidence shows early brain injury (EBI) [6-10] enrolled cortical spreading depression, early cortical depolarization waves, and impaired neurovascular coupling, play key roles in neurological deterioration after SAH. Connolly stated the mortality rate in SAH patients remained 27% to 44%, and more than half of all SAH patients survive with serious cognitive and functional impairment [11]. These results stimulate efforts to dissect the cellular and molecular basis of EBI accompanying SAH to establish rational therapeutic targets.

Blood clots, existing in the subarachnoid space, are able to induce acute arteries and arteriolar constriction, passive venous obliteration and delayed arterial spasm [1, 11-12]. Previous studies have focused on
the vasoconstriction of arteries; however, the precise mechanism and pathogenesis of arteriolar constriction and venous obliteration associated EBI remain unclear. A growing body of both direct and indirect evidence shows possible mechanisms to produce EBI include oxidative stress,[13] nitric oxide(NO)/nitric oxide synthase(NOS) uncoupling [14], matrix metalloproteinase -9 (MMP-9) induced BBB breakdown [15], nuclear factor erythroid related factor 2 (Nrf2) pathway related oxidation [16], activation of c-Jun N-terminal kinase pathway, [14,17,18] increased proinflammatory cytokines [19] vascular endothelial growth factor, and mitogen-activation protein kinase [20]. Energy over-loaded after hemoglobin degrading has been shown to induce EBI. Owing to lack of effective therapies to achieve a better outcome in SAH patients, studies have become focused on the pathogenesis of EBI.

Parecoxib, a intravenous administration form of a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug (named celecoxib), is used to treat osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and juvenile rheumatoid arthritis [7]. COX (a prostaglandin H (PGH) synthase) is a key regulatory enzyme that catalyzes the conversion of arachidonic acid and associated prostaglandin (PG) G2 and PGH2 to a variety of eicosanoids, such as PGE2, PGD2, PGF2a, PGI2, and thromboxane (TX) A2 [21]. Recently, COX-2 inhibitor has been reported to have a neuroprotective effect in the experimental intracerebral hemorrage model as well as induce apoptosis in Huh7 and HepG2 cell line cultures [22]. In the study of SAH rabbits, intramuscular administration of parecoxib was shown to attenuate SAH induced vasospasm and basilar artery wall thickness [23]. Owing to the concerning side effects of major cardiovascular events, increased risk could be avoided by shortening the duration of administered COX-2 inhibitor and reducing the therapeutic dosage in patients who have pre-existing cardiovascular risk factors or disease. In this study, parecoxib was administered via an osmotic mini-pump at a minimum dosage and within a short duration, devoid the mentioned side effect of cardiovascular and renal problems. 0.9% saline was used as a vehicle.

Taking these findings together, we propose that COX-2 inhibitors, with its unique property in PGs expression, may be effective in SAH-induced EBI. Given the importance of arterial lesion formation, associated pro-inflammatory cytokine stimulation on leucocyte and endothelial dysfunction in the rat SAH model was used to test the hypothesis that COX-2 inhibitor significantly attenuates caspase-related apoptosis and C-Jun N-terminal kinase (cJNK)-associated inflammation following experimental SAH.

Methods

Materials

Parecoxib has been previously characterized as a potential inhibitor of COX-2 and was bought from Sigma Laboratory, Taipei, Taiwan. Monoclonal anti-rat IL1-β, IL-6, IL-8, NeuN, MCP-1 and GFAP antibody were obtained from Abcam (Cambridge, MA 02139-1517, USA), Upstate Biotech (Lake placid NY, USA), and Santa Cruz Biotech (Santa Cruz Biotechnology, Inc. Santa Cruz, CA 95060, USA), respectively. Rabbit anti-rat cJNK (p55 and p46) antibody was obtained from Santa Cruz Biotechnology, Inc. Santa Cruz, CA 95060, USA). Parecoxib in a mini-pump was prepared by Ms. Wu SC (Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, ROC), and 0.9% saline was used as a vehicle.

Induction of experimental SAH

Fifty-four male Sprague-Dawley rats, weighing between 320–450 g (BioLasco Taiwan Co., Ltd., authorized by Charles River Lab), were used in this study. All the experimental protocols were authorized and supervised by the University of Kaohsiung Medicine Animal Research Committee. The rats received anesthesia by an intra-peritoneal injection of a mixture of 0.9 mg/100 gm xylazine and 5.0 mg/100 gm Ketavet. 0.1 ml fresh arterial blood was withdrawn and injected into the cisterna magna using a stereotactic apparatus (Stoeling, Wood Dale, IL, 60191, US) [24,25]. After the induction, animals were placed in ventral recumbent position for 30 minutes to let ventral blood clot formation. After monitoring for respiratory distress and giving mechanical ventilation if necessary, the animals were returned to the vivarium until becoming fully awake. A habitat with a 12 hr light-dark cycle and access to food and water ad lib was offered.

General design of experiments and treatment groups

The animals were subdivided into the following groups (9 rats/group): 1) sham operated (no SAH); 2) SAH only; 3) SAH plus vehicle; 4) SAH plus parecoxib (500 ug/kg/day); 5) SAH plus treatment with parecoxib (1000 ug/kg/day); and 6) treatment with 2000 ug/kg parecoxib in SAH rats. The dosage was adjusted according to our pilot study, devoid of hepato-renal toxicity and G-I bleeding. The first injection was given at 1hr after induction of SAH by using an omotic mini-pump (Alzet corp, Palo Alto, CA 94301, USA). After re-anesthesia, CSF sampling was obtained through a 30-gauge needle into the cranial-cervical junction by using stereotactic apparatus. The animals were sacrificed by perfusion–fixation 72hr after SAH. Cortical tissue were sampled by means of placing a 22-gauge needle inserted 3 mm in depth into the skull bone (N=5) through a burr hole craniectomy (2 mm apart from the bregma) at a 24 hr interval.

Perfusion–Fixation

By the end of the study, the animals were re-anesthetized by administration of 7 mg/kg Zoletil 50 (a combination of tiletamine hydrochloride and zolazepam hydrochloride. VIRBAC, L.I.D., Carros 06516, France). The femoral artery was catheterized to monitor blood pressure and obtain blood samples to determine arterial blood gas, BUN, Cr, GOT and GPT levels. Perfusion–fixation was performed as opening the thorax, and the left ventricle was cannalled with a NO18 catheter with clamping the descending aorta, and opening the right atrium. 120 ml of 70 mm Hg of 0.01M phosphate buffer (pH 7.4) was used for perfusion, followed by fixation with 120 ml 2% paraformaldehyde in the PBS solution at 36°C under a perfusion pressure of 80 mm Hg. The harvested brain was immersed in a fixative at 4°C overnight. Visual inspection made sure that formed blood clots covered the basilar artery (BA) in all SAH animals.

Hemodynamic measurements

Heart rate, blood pressure, and rectal temperature were monitored before and after parecoxib administration at intervals of 12hr after the induction of SAH by a tail-cuff method (SC1000 Single Channel System, Hatteras Instruments, NC, 27518, USA) and rectal thermometer (BIO-BRET-2-Iso. FL 33780, USA).
Neurological assessment

A modified limb-placing tests (MLPT), [26] and a modified Voetsch neuro-score test [27] were performed before and at 24hr after the induction of SAH by an investigator blinded to the experiment set. The behavioral examination comprised two parts: ambulation and placing/stepping reflex examinations were performed before and after animals were subjected to SAH. The modified limb-placing tests (MLPT) was composed of two limb-placing tasks to examine the sensorimotor integration of the forelimb and the hindlimb through tactile and proprioceptive stimulation. The ambulation task was performed by suspending the rat 10 cm over a table and evaluated the stretch of the forelimbs towards the table: normal stretch, 0 points; abnormal flexion, 1 point and then, by positioning the animal along the edge of the table, and let its forelimbs placed out of the edge and allowed to move freely. The same performance of hindlimb was checked as normal performance, 0 point; performance with a delay (2 s) and/or incomplete, 1 point. A motor deficit index (MDI) was calculated for each rat at a set time interval. The final index was the sum of the scores of walking with lower extremities and placing/stepping reflex. Animals with MDI score more than three were defined as paraplegic, whereas animals with MDI score less than three were regarded as neurological deficit. The modified Voetsch neuro-score was to evaluate the head movement, confrontation, reflex stimulated by ear pinch, proprioception and four limbs movement. The modified Voetsch neuroscore is a vertebrobasilar scale score of sensorimotor ability. To examine the spontaneous movement of head: moves in all dimensions, 3 points; prefers one side, 2 points; only movement to 1 side, 1 point; flexed to unilateral side, 0 point. Confrontation task was defined as: fully responsive, 3 points; moderately responsive, 2 points; minimally responsive, 1 point and coma, 0 point. The hearing test by auditory startling: finger rubbing, 3 points; snap of fingers, 2 points, loud clapping, 1 point and no startling, 0 point. Pain reflex after ear pinch: brisk and symmetrical reaction, 3 points; slightly diminished or asymmetrical reaction, 2 points; severely diminished and asymmetrical reaction, 1 point; no reaction, 0 point. To check the sensation of the neck in a cage: reached 2 walls, 3 points; touched 1 wall, 2 points; moved along the base, 1 point and no movement, 0 point. To check cranioocular movement, turned bilaterally, 3 points; preferred circling 1 side, 2 points; only turned circling to 1 side, 1 point; fallen to 1 side, 0 point. To test the axial sensation, brisk and symmetrical reaction to stimuli, 3 points; slightly diminished or asymmetrical reaction, 2 points; greatly diminished and asymmetrical movement, 1 point and no reaction, 0 point. To evaluate forelimb and hindlimb movement: equal and bilateral movement, 3 points; slight asymmetry, 2 points; prominent asymmetry, 1 point; paresis, 0 point. To check the ability to climbing, the rat is able to climb to top, 3 points; impaired climbing, 2 points; stationary gripping, 1 point and fell immediately, 0 point. The final stage is to examine movement to the stimuli of beam, explored both ends, 3 points and some movements, 2 points. The sum of neuroscores ranged from 0 to 30, which stood for normal performance to comatose status and paraplegia.

Quantification of mRNA expression of IL-1β, IL-6, IL-8, and MCP-1

ABI PRISM 7900 System (Applied Biosystems, Foster City, CA, 94404, USA) was used to examine the expression of cytokines mRNA. As indicated by the manufacturer’s instructions, the mRNAs for IL-1β, IL-6, IL-8, and MCP-1 expression were estimated, while 18S was assigned as a housekeeping gene owing to its stable expression in the condition of SAH stimuli. Each sample was launched into a TaqMan® Human Cytokine Card that enclosed probes and primers for specific targets as well as the 18S ribosomal RNA as a standard control. This procedure was performed through an affixed filling reservoir and a vacuum loading process via the ABI PRISM® Card Filling Station.

Target mRNAs were standardized according to the reference gene (18S), and final data were expressed as a relative fold from baseline values. Comparative mRNA expression was set by the Livak and Schmittgen method [30]. The results were analyzed once a 5-fold increase was observed in the mRNA levels compared with baseline to let data consistent.

Immu-no-blotting for cJNK (p55 and p46)

To evaluate glia-mediating neuro-inflammation, the protein expression of JNK in brain tissue homogenates was evaluated via western blot analysis. Samples containing 30µg of protein stirred with LDS sample buffer (contains 40% glycerol, 4% lidodeyl sulfate (LDS)), 0.8 M triethanolamine-CI pH 7.6, 4% Ficol 400–0.005, 0.025% phenol red, 0.025% Coomassie G250, 2 mM EDTA disodium, NuPAGE® LPS Sample Buffer (4×) NP0007, Invitrogen, Carlsbad, CA 92008, USA). Samples were then obtained after being loaded for 8% sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then separated after centrifuging at 15,000 rpm for 10 min. The sample was mounted onto a polyvinylidene difluoride membrane and then incubated in blocking buffer (5% non-fat dry milk in Tris-buffered saline with 0.2% Tween 20) at room temperature. Rabbit anti-rat cJNK polyclonal antibody (1:200; Chemicon International, Temecula, CA 92590, USA) was used as a control. A secondary antibody was conjugated with horseradish peroxidase (HRP) in TBS-t at room temperature for 1hr. Optical densities were measured by an enhanced Pierce chemiluminescent image analyzer (a GS-700 digital densitometer, GMI, Ramsey, MN 55303, USA).

J Neurol Neurophysiol
ISSN:2155-9562 JNN, an open access journal
Volume 6 • Issue 3 • 1000294
The analysis of NMDAR -1, -2a, -2b by western blotting

The cortical homogenates were centrifuged at 15,000 rpm for 10 min twice. The protein extracts (30ug) were obtained via 10% sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen) and then transmitted onto a nitrocellulose membrane. These membranes were further nurtured in a blocking buffer, composed of 5% skim milk in Tris-buffered saline containing Tween 20 (TBS-t) (50 mmol/L Tris, pH 7.5, 0.15 mmol/L NaCl, 0.05% Tween 20) , and incubated with anti-NMDAR-2a (1:1000), anti-NMDAR-2b (1:1000), anti-NMDAR-1 (1:1000), and anti-HO-1 (1:1000) in TBST overnight at 4°C. The incubated membranes were treated with secondary antibody conjugated with horseradish peroxidase (HRP) in TBS-t at room temperature for 1hr. Anti- β-actin antibody was used as a standard control. The immunoblots were developed via a GS-700 digital scan and Molecular Analyt®. Relative optical densities were obtained by comparison between the measured values and the mean values from the vehicle plus SAH groups.

Estimation of Bcl-2, cleaved caspase -3 and -9a mRNA by rt-PCR

The levels of activated caspase-3 and caspase-9a mRNA in the cortical homogenates were determined by TriPure RT-PCR Reagent (Roche Diagnostics Corp. IN, 46256, USA). According to the supplier’s instructions, the PCR primer sequences were designed according to the cleaved caspase-3, and -9a and glyceraldehyde-3-phosphate dehydrogenase (GAPDH as a standard control) gene sequences in GenBank. Bcl-2 (231bp; forward: 5’- CGTTACGGCCCAAGCATGGC-3’; reverse: 5’- GCCTTTGGTCTATGGTACATC-3’); Caspase-3 (393bp; forward: 5’- GGTATTGAGACAGACAGTGG-3’; reverse: 5’- CCAGTGAGTTTCCCGGTTG-3’); GAPDH (347bp; forward: 5’- GGAGCCAAAAGGGTCATC-3’; reverse: 5’- GCTTTGTTTCATGGTACATC-3’); Caspase-9 (889bp; forward: 5’- GGTATTGAGACAGACAGTGG-3’; reverse: 5’- CCAGTGAGTTTCCCGGTTG-3’). After incubation with Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) (Promega, WI 53711, USA), the cleaved caspase -3, -9a and GAPDH cDNA were amplified. The amplified cDNA fragments were detected via agarose gel electrophoresis swirled with 1 μL of ethidium bromide. The intensity of the bands was measured via a comet assay method. Owing to its stable expression under subarachnoid hemorrhage stimuli, GAPDH mRNA was used as a housekeeping gene for multiplexing. The tissue of every five animals was used for rt-PCR and three measurements for each animal specimen performed to obtain a mean value. The pro-caspase-9 was catalyzed and cleaved into caspase-9a (majority) and -9b. We chose cleaved caspase-9a to represent the activated caspase-9.

Statistical analysis

Data are expressed as the means ± standard deviation. For group comparisons, one-way analysis of variance was used for analyses (ANOVA) followed by the Newman-Keuls post-hoc test and the Student t test statistically. Difference, at a probability value less than 0.01, was considered significant.

Results

General observation

Through all the course of this experiment, all animals showed no significant differences in the physiological parameters recorded, including glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), blood urea nitrogen (BUN), creatinine, pH, blood pressure and arterial blood gas analysis among all groups. It proved that continued parecoxib pumping in the selected dosage has a number of pleiotropic effects, but devoid of hepatic and renal toxicity and bowel bleeding (Table 1). According to the brain edema after the induction of SAH, there is no significant difference among all the experimental groups (Figure 1, lower panel). Increased MCP-1(+) cells in the adventitia of vascular wall, NeuN (+) neurons with vacuolar formation in the cortex and GFAP(+ ) astrocytes were observed in the SAH groups, when compared with the parecoxib treatment SAH group, which correspond to the observation of MCP-1 mRNA (Figure 1 upper and middle panels).

Table 1: Physiological parameters among the groups; Results are expressed as the mean ± SEM, n = 9; p< 0.01 versus SAH condition by Mann-Whitney U test.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Body weight (g)</th>
<th>Systolic B.P.</th>
<th>GOT/GPT (IU/L)</th>
<th>BUN/Cr (mg/dL)</th>
<th>pH</th>
<th>Temperature(°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sham</td>
<td>352 ± 31</td>
<td>107 ± 16</td>
<td>8.2 ± 2.4/4.0</td>
<td>8.1 ± 1.0/0.6</td>
<td>7.3</td>
<td>37.2 ± 0.4</td>
</tr>
<tr>
<td>SAH</td>
<td>331 ± 50</td>
<td>111 ± 18</td>
<td>10.3 ± 3.0/4.6</td>
<td>8.6 ± 0.7/0.8</td>
<td>7.3</td>
<td>37.0 ± 0.6</td>
</tr>
<tr>
<td>SAH + Parecoxib</td>
<td>342 ± 48</td>
<td>102 ± 36</td>
<td>10.5 ± 4.0/9.1</td>
<td>10.5 ± 3.1/0.8</td>
<td>7.3</td>
<td>36.9 ± 0.5</td>
</tr>
</tbody>
</table>

Table 1: Physiological parameters among the groups; Results are expressed as the mean ± SEM, n = 9; p< 0.01 versus SAH condition by Mann-Whitney U test.

Neurological deficit after SAH

A summary score of four limbs ambulation was obtained to assess the sensorimotor incorporation of the forelimb and hindlimb, and placing/stepping reflex as a reflective response to tactile and proprioceptive stimuli in the SAH groups was significantly higher than the healthy controls and parecoxib groups. The sum of these two tests
was considered as motor deficit index (MDI). The values of MDI in the SAH and SAH+vehicle groups were 2.92 ± 0.46 and 2.87 ± 0.40 respectively, compared with a score of 0 and 1.20 ± 0.46 in the healthy controls and 2000ug/kg parecoxib respectively. Treatment with parecoxib significantly improved the MDI in the SAH groups (Table 2). The modified Voetsch neuro-scores were dose-dependently improved in the parecoxib + SAH group and the healthy controls when compared with the SAH groups (Table 3).

Table 2: Modified limb-placing test (MLPT); Results are expressed as the mean ± SD, n = 9; * p< 0.01 versus SAH condition by Mann-Whitney U test.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Head movement</th>
<th>Motor-sensory function</th>
<th>4-limb movement</th>
<th>Sum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham-operated</td>
<td>12 ± 0</td>
<td>12 ± 0</td>
<td>6 ± 0</td>
<td>30 ± 0</td>
<td></td>
</tr>
<tr>
<td>SAH</td>
<td>5.2 ± 2.8</td>
<td>5.2 ± 3.0</td>
<td>2.8 ± 0.6</td>
<td>13.2 ± 6.4</td>
<td></td>
</tr>
<tr>
<td>SAH+ Vehicle</td>
<td>5.6 ± 3.4</td>
<td>5.4 ± 3.2</td>
<td>3.0 ± 2.1</td>
<td>14.0 ± 5.5</td>
<td></td>
</tr>
<tr>
<td>SAH+Parecoxib</td>
<td>6.4 ± 2.4</td>
<td>7.0 ± 3.2</td>
<td>3.6 ± 1.2</td>
<td>16.1 ± 6.8</td>
<td></td>
</tr>
<tr>
<td>500ug/kg/day</td>
<td>9.2 ± 3.2</td>
<td>8.6 ± 2.8</td>
<td>4.4 ± 1.8</td>
<td>22.2 ± 7.8</td>
<td></td>
</tr>
<tr>
<td>1000ug/kg/day</td>
<td>11.4 ± 3.3*</td>
<td>10.6 ± 3.0*</td>
<td>5.1 ± 2.4</td>
<td>27.1 ± 8.7*</td>
<td></td>
</tr>
<tr>
<td>2000ug/kg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3:  Modified Voetsch neuroscores. Results are expressed as the mean ± SD, n = 9; * p< 0.01 versus SAH condition by Mann-Whitney U test.

mRNA expression of IL-1β, IL-6, IL-8, and MCP-1

After SAH, the CSF levels of IL-1β, IL-6, IL-8, and MCP-1 were found to increase 1000- and 3000-fold at 72hr, when compared with the sham operated group. Administration of 2000 ug/kg parecoxib reduced cytokine levels by 7%, 25%, 42% and 21% for IL-1β, IL-6, IL-8, and MCP-1 respectively, 24hr after SAH (Figure 2). Level of IL-1β was reduced in the parecoxib treatment groups in a dose-dependent mechanism in this study. 2000 ug/kg/day parecoxib significantly reduced the levels of IL-1β, IL-6 and MCP-1 in animals at the time points of 24hr and 72hr after the induction of SAH. Meanwhile, treatment with parecoxib tended to reduce the level of pro-inflammatory cytokines; the IL-8 level (at 72hr) failed to achieve statistical difference from the SAH group (Figure 2).

cJNK (p55/p46) expression

The cJNKs were demonstrated to play a pivotal role in the early cascades of pro-apoptotic signaling. cJNK was chosen as an example of modulating the program for cellular survival and differentiation, which has emerged as a key molecule in regulating the pathogenesis of SAH-induced EBI. In this study, parecoxib dose-dependently reduced the expression of cJNK (p55) in SAH animals. (Figure 3, p<0.01)

The expression of NMDAR-1, NMDAR-2a, and NMDAR-2b protein

To examine the glutamate-related neuronal death in animals subjected to SAH, NMDAR-1, NMDAR-2a and NMDAR-2b was used via rt-PCR (Figure 4). The level of NMDAR-1 protein was significantly
induced in the SAH groups (SAH only, treatment with vehicle) when compared with the sham-operated groups (p<0.01). Parecoxib (at 1000 and 2000 ug/kg/day) decreased NMDAR-2a expression when compared with the SAH groups (P<0.01). Parecoxib dose-dependently reduced the expression of NMDAR-1 (P<0.01). Increased NMDAR-2b expression was noted in all the SAH groups (Figure 4, P >0.01).

The expression of activated Caspase-3 and -9a mRNA

Cleaved caspase-3 and -9a (the major functional variant) were used to examine the neuronal apoptosis. The activated caspase-9a was observed to increase in the SAH groups when compared with the sham-operated groups (p<0.01). 1000 ug/kg and 2000 ug/kg parecoxib decrease cleaved caspase-3 level when compared with the SAH groups respectively (Figure 5, p<0.01). Only high-dose parecoxib could attenuate apoptosis-related caspase-9a and caspase-3 when compared with the SAH groups.

**Figure 2:** Bar graph depicting parecoxib on the time-course (24hr and 72hr) change of pro-inflammatory cytokines after induction of SAH. Data are depicted for IL-1β, IL-6, IL-8, MCP-1. Although trends to decrease in IL-8 and IL-6, the effect of parecoxib is relevant to IL-1β and MCP-1. Data in the figure are presented as mean ± SD(n = 9). *, **, ***: P<0.01, and #, ##, ###: P>0.01 when compared with the SAH group.

**Figure 3:** The immunohistochemical study of cJNK( P55/P46) expression (western blot). Upper panel represents the western blot of the SAH only group (A), the SAH + vehicle group (B), 500ug/kg/day parecoxib treatment SAH group (C), 1000ug/kg/day parecoxib treatment in SAH rats (D) and SAH animals received 2000ug/kg/day parecoxib treatment (E). Bar graphs revealed the assay showed induced cJNK immunoreactivity in the SAH groups when compared with the control group. Parecoxib dose-dependently reduced the expression of cJNK when compared with the SAH groups. Data in the figure are presented as mean ± SD. (*,**: P<0.01, #: P>0.01, indicates comparison among the 500, 1000, 2000ug/kg parecoxib and SAH groups respectively. )

**Figure 4:** Bar graph demonstrating parecoxib on the expression of NMDAR-1, NMDAR-2a, and NMDAR-2b protein (western blot). Top panel: all groups are identified to those stated in the legend of Figure 3. Bottom panel shows parecoxib is able to decrease the expression of NMDAR-2b (at high dose), and NMDAR-2a (dose-dependently), but does not decrease SAH-induced NMDAR-1 expression. All values are mean ± SD. *, **: P<0.01, and #, ##, ###: P>0.01, compared with the SAH group.
To assess the regulation of apoptosis through mitochondrial cytochrome c release, Bcl-2 mRNA was evaluated. The Bcl-2 mRNA was induced in the treatment of 2000 ug/kg/day parecoxib in SAH rats, when compared with the SAH group (Figure 6, p<0.01). The bar graphs revealed 1000ug/kg and 2000ug/kg parecoxib decreased caspase-3 level when compared with the SAH groups. Parecoxib, at high dose, can attenuate apoptosis-related caspase-9 and caspase-3 when compared with the SAH groups. Data are shown as mean ± SD. (*, **: P<0.01, and #, ##: P>0.01)

**Figure 5:** Levels of cleaved caspase-3 and -9a in the SAH rats receiving parecoxib treatment (rt-PCR). Top panel: all groups are the same as those stated in the legend of Fig.3. 2000ug/kg parecoxib significantly decreased caspase-9a in the SAH rats (p<0.01). The bar graphs revealed 1000ug/kg and 2000ug/kg parecoxib decreased caspase-3 level when compared with the SAH groups. Parecoxib, at high dose, can attenuate apoptosis-related caspase-9 and caspase-3 when compared with the SAH groups. Data are shown as mean ± SD. (*, **: P<0.01, and #, ##: P>0.01)

**ApoPrimer for Bcl-2 mRNA**

To assess the regulation of apoptosis through mitochondrial cytochrome c release, Bcl-2 mRNA was evaluated. The Bcl-2 mRNA was induced in the treatment of 2000 ug/kg/day parecoxib in SAH rats, when compared with the SAH group (Figure 6, p<0.01).

**Figure 6:** Level of activated Bcl-2 mRNA in the SAH rats receiving parecoxib treatment (rt-PCR). The bar graph shows parecoxib treatment dose-dependently induced Bcl-2 level in the SAH rats (p<0.01). Top panel: all groups are an exact copy of those stated in the legend of Fig. 3. The Data are showed as mean ± SD. (*: P<0.01; comparison among the treatment with parecoxib and SAH groups).

Page 8 of 10

The mechanism that parecoxib exerts anti-apoptotic effect via family members, designated BH1, BH2, BH3, and BH4 [43,44]. An inducing cytoplasm Bcl-2 expression merits a further study lateral. MAPK-related molecules, microRNA was able to suppressed targeting to membranes such as the mitochondrial outer membrane. Increased adhesion molecules and pro-inflammatory cytokines were observed increased in cerebrospinal fluid (CSF) after subarachnoid SAH [5,24]. However, the relationships among the development of inflammatory response, early brain injury, and delayed cerebral ischemia in the brain after SAH need to be clarified. The cumulative findings indicate that the up-regulation of pro-inflammatory cytokines is antecedent to radiographic vasospasm (peak at 4th to 14th days after SAH) in human, and attenuation of cytokines tends to minimize vascular constriction and reduced early brain ischemia in animals.

Microcytochrome c release [43]. Caspase-9 behaves as an initiator and has been shown able to uncouple the mitochondria and increase ROS production [13,40]. In this study, parecoxib was observed able to reduce the caspase-9a (2000 ug/kg/day) and decrease caspase-3 (of a dosage of 1000 and 2000 ug/kg/day). It is believed parecoxib, at a selected dosage, has a neuroprotective effect by blocking both initiator caspase-9a and effector caspase-3 activation.

Four conserved Bcl-2 homology (BH) domains were found in Bcl-2 family members, designated BH1, BH2, BH3, and BH4 [43,44]. An anti-apoptotic characteristic was conserved in a carboxy-terminal hydrophobic domain, through which BCL-2 is essential for its targeting to membranes such as the mitochondrial outer membrane [44]. The anti-apoptotic molecules, such as Bcl-2 or Bcl-XL, can inhibit the activation of BAX following a death signal. In contrast to inactive Bax, [43] Bcl-2 is an integral membrane protein heavily localized to mitochondria, exerts an anti-apoptotic effect. 2000 ug/kg/day parecoxib enhanced the cytoplasm Bcl-2 in the SAH study. The mechanism that parecoxib exerts anti-apoptotic effect via inducing cytoplasm Bcl-2 expression merits a further study lateral.

Increased adhesion molecules and pro-inflammatory cytokines were observed increased in cerebrospinal fluid (CSF) after aneurismal SAH [5,24]. However, the relationships among the development of inflammatory response, early brain injury, and delayed cerebral ischemia in the brain after SAH need to be clarified. The cumulative findings indicate that the up-regulation of pro-inflammatory cytokines is antecedent to radiographic vasospasm (peak at 4th to 14th days after SAH) in human, and attenuation of cytokines tends to minimize vascular constriction and reduced early brain ischemia in animals.

Monocyte chemoattractant protein-1 (MCP-1) is able to predict outcome and vasospasm following aneurismal SAH and is highly expressed to reduce the tight junctions of vascular endothelium [19,46]. Elevation in the mRNA levels for IL-1β, IL-6, IL-8, TNF-αand pro-inflammatory enzyme-caspsases-1, -4, -5, -11, -12, and -13, caspase-3, -6, and -7, and the other include pro-inflammatory enzyme-enrolled caspsases-1, -4, -5, -11, -12, and -13. Caspase-3 is believed to be the major effecter caspase in neuronal apoptosis [42]. It has been observed that caspsases act on upstream intrinsic apoptosis, and on downstream of cytochrome c release [43]. Caspase-9 behaves as an initiator and has been shown able to uncouple the mitochondria and increase ROS production [13,40]. In this study, parecoxib was observed able to reduce the caspase-9a (2000 ug/kg/day) and decrease caspase-3 (of a dosage of 1000 and 2000 ug/kg/day). It is believed parecoxib, at a selected dosage, has a neuroprotective effect by blocking both initiator caspase-9a and effector caspase-3 activation.

cJNK, belonging to the family of mitogen-activated protein kinase (MAPK), plays a role in T cell differentiation and cellular apoptosis pathway [14,39]. Though mediated by regulated-upon-activation normal T cell expression and presumably secreted (RANTES) and colony stimulating factor 2 (CSF2), cJNK is believed to be able to modulate cellular apoptosis, neuro-degeneration, proliferation and differentiation, cytokine production and subsequent inflammatory reactions [17]. In Jadhav et al.'s study, through modulating cJNK/ MAPK-related molecules, microRNA was able to suppressed microglia-elicited neuro-inflammation [18]. In the study of Hela cell culture, cleaved caspase-3 was demonstrated to disassemble the JIP1/JNK complex and set off the initiation of apoptosis, which corresponds to our findings [17]. Through suppression of cleaved caspase-3 (at a dosage of 1000 and 2000 ug/kg/day), parecoxib was able to reduce cJNK, and attenuated associated cytokine activation.

In summary, the results of this study show that continued administration of parecoxib, at a selected dosage, is safe and efficacious in the prevention of EBI in this experimental model and is meritorious of further investigation. Decreased levels of NMDAR-1 as well as caspase-3 may contribute to the anti-apoptotic effect of this compound. Besides, parecoxib, by reducing cJNK activation, exerts a dual effect on the MAEK-related apoptotic pathway and IL-1β related inflammatory cascade.

Conclusion

The outcome of SAH patients is persistently devastating, and has changed little after decades of research and treatment focusing on cerebral vasospasm. These accumulated results arouse interest to consider the pathogenesis of SAH-induced EBI and its effects dictating the patient's outcome. The ultra-short activated cyclooxygenase-2 following SAH leads a cascade of neuro-inflammatory reaction. The breakthrough of BBB accompanying SAH may be another complicated pathway underlying the development and maintenance of EBI. This study shows that administration of parecoxib diminishes SAH-induced cerebral edema and subsequent glutatione-related excitotoxicity in a rodent model of SAH. This study suggests that parecoxib, an early cyclooxygenase-2 inhibitor, could prove clinically useful in treating SAH-induced early brain injury.

Acknowledgement

Chang CZ, M.D., Ph.D. assisted in the planning and composing the manuscript; Wu SC, Master, helped the data collection and carried out the study. Lin CL, M.D., Ph.D. help the grand gathering and Kwan AL, M.D., Ph. D. for her assistance in the experimental planning and support.

References


---
